226 related articles for article (PubMed ID: 35894280)
1. Progress in the management of patients with diabetes and chronic kidney disease.
Pozo Garcia L; Thomas SS; Rajesh H; Navaneethan SD
Curr Opin Nephrol Hypertens; 2022 Sep; 31(5):456-463. PubMed ID: 35894280
[TBL] [Abstract][Full Text] [Related]
2. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
3. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB; Pergola P
Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
6. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Shi Q; Nong K; Vandvik PO; Guyatt GH; Schnell O; Rydén L; Marx N; Brosius FC; Mustafa RA; Agarwal A; Zou X; Mao Y; Asadollahifar A; Chowdhury SR; Zhai C; Gupta S; Gao Y; Lima JP; Numata K; Qiao Z; Fan Q; Yang Q; Jin Y; Ge L; Yang Q; Zhu H; Yang F; Chen Z; Lu X; He S; Chen X; Lyu X; An X; Chen Y; Hao Q; Standl E; Siemieniuk R; Agoritsas T; Tian H; Li S
BMJ; 2023 Apr; 381():e074068. PubMed ID: 37024129
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV
Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials.
Yang Q; Lang Y; Yang W; Yang F; Yang J; Wu Y; Xiao X; Qin C; Zou Y; Zhao Y; Kang D; Liu F
Diabetes Res Clin Pract; 2023 Apr; 198():110592. PubMed ID: 36842477
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
[TBL] [Abstract][Full Text] [Related]
13. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
Kim DL; Lee SE; Kim NH
Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
[TBL] [Abstract][Full Text] [Related]
14. A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients.
Spasovski G; Rroji M; Hristov G; Bushljetikj O; Spahia N; Rambabova Bushletikj I
Metab Syndr Relat Disord; 2024 Apr; 22(3):170-178. PubMed ID: 38386800
[TBL] [Abstract][Full Text] [Related]
15. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials.
Chaudhuri A; Ghanim H; Arora P
Diabetes Obes Metab; 2022 Mar; 24(3):365-376. PubMed ID: 34779091
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease.
Tsujimoto T; Kajio H
Eur J Prev Cardiol; 2018 Aug; 25(12):1268-1277. PubMed ID: 29808753
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
Kintscher U
Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with kidney protective therapies: optimizing the benefits?
Kotwal S; Perkovic E; Perkovic V
Curr Opin Nephrol Hypertens; 2024 Jan; 33(1):136-143. PubMed ID: 37767945
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.
Cohen S; Sternlicht H; Bakris GL
Curr Diab Rep; 2022 May; 22(5):213-218. PubMed ID: 35441935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]